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Introduction: In the International Statistical Classification of Diseases and Related Health Problems 10 and
Diagnostic and Statistical Manual of Mental Disorders IV classification systems, catatonia is classified as a subtype of
schizophrenia. However, catatonia is more frequently associated with mood disorders than schizophrenia. It is also
associated with organic conditions. Catatonia responds to treatment with benzodiazepines and electroconvulsive
therapy rather than antipsychotics. These features support the categorization of catatonia as an independent
syndrome. There is a lack of consensus regarding the definition of chronic catatonia. There are two previous case
reports of effective treatment of chronic catatonia with electroconvulsive therapy.
Case presentation: A 29-year-old South Asian woman was admitted to hospital because of poor food intake.
Her condition had progressively worsened over the past seven months. She had features of catatonia. On
admission, her Bush-Francis Catatonia Rating Scale score was 24. Her symptoms resolved after the administration
of 17 electroconvulsive therapies but recurred later. She was given a further four electroconvulsive therapies.
She remains well on aripiprazole at a dose of 60mg a day.
Conclusions: Bilateral electroconvulsive therapy is effective in the treatment of chronic catatonia and should be
considered as a treatment option. A relapse of symptoms can occur after the discontinuation of treatment.
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The Diagnostic and Statistical Manual of Mental Disorders,
fourth edition (DSM IV) describes catatonia as a syndrome
with marked psychomotor disturbance that may involve
motor immobility, excessive motor activity, extreme nega-
tivism, mutism, peculiarities of voluntary movement, echo-
lalia or echopraxia [1].
Catatonia was first described by Kahlbaum as a disorder
of movement and speech. Kraepelin grouped together
catatonia, hebephrenia and paranoid psychosis, as demen-
tia praecox. Eugen Bleuler later coined the term schizo-
phrenia for this condition.
In the International Statistical Classification of Diseases
and Related Health Problems (ICD-10) and DSM IV clas-
sification systems, catatonia is classified as a subtype of
schizophrenia [1,2]. However catatonia is more frequently
associated with mood disorders than schizophrenia [3]. It* Correspondence: varunidesilva2@yahoo.co.uk
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reproduction in any medium, provided the oris also associated with organic conditions. Unlike other
subtypes, the core features of schizophrenia, delusions
and hallucinations, are not characteristic of catatonia.
Catatonia responds to treatment with benzodiazepines
and electroconvulsive therapy (ECT) rather than anti-
psychotics. These features support the categorization of
catatonia as an independent syndrome [3].
Taking into account the current scientific evidence,
the DSM-5 made several changes in the classification of
catatonia [4]. ‘Schizophrenia, catatonic type’ has been
eliminated. Catatonia is included as a specifier across the
10 principal primary diagnoses. The subcategory ‘catatonia
associated with another mental disorder’ is retained and
a new subcategory of ‘unspecified catatonia’ has been
included.
Benzodiazepines are effective in the treatment of acute
catatonia [5]. The motor symptoms of acute catatonia
probably occur due to a deficiency of cortical gamma-
aminobutyric acid (GABA). Benzodiazepines increase
GABA activity, which could explain their therapeutic ef-
fect in catatonia. Some patients with chronic catatonial Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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durations [6-8]. Manjunatha et al. report that a 28-year-
old woman with recurrent catatonia responded initially
to lorazepam 4mg a day, but symptoms recurred when
the dose was reduced to 2mg a day [7]. The catatonic
episodes recurred five times in six months and each
time the symptoms responded to lorazepam 6mg a day.
Mukai et al. reported that a patient with chronic cata-
tonia responded to daily doses of clozapine 300mg and
lorazepam 1mg [8]. Grover et al. report that a 38-year-
old woman with chronic catatonia responded to loraze-
pam 6mg a day, imipramine 175mg a day and risperidone
4mg a day. This patient developed catatonic symptoms
each time the lorazepam was tapered off, therefore she
was maintained on lorazepam for more than two years [6].
Another case report describes that lorazepam was effec-
tive in the treatment of chronic ‘speech catatonia’ [9].
Gaind et al. report that chronic catatonia in a mentally
retarded man responded to high doses of lorazepam
after five months of treatment [10]. However, a 12-
week crossover randomized trial found that lorazepam
6mg a day was not effective in the treatment of chronic
catatonia [4].
There are only two previous case reports of chronic
catatonia treated with ECT. One patient was a 41-year-
old Asian woman with schizophrenia with intermittent
catatonic symptoms of 12 years’ duration [11]. She was
treated successfully with eight ultrabrief pulse width
right unilateral treatments given at six times seizure
threshold. The other case report is of a 25-year-old
woman with features of catatonia who was administered
bilateral ECT [12]. In this patient, bilateral ECT was ad-
ministered twice a week (impulse width 0.5 msec, energy
set first 53 treatments 5% to 100% and second 15 treat-
ments 5% to 35%). The catatonic symptoms reappeared
when ECT was stopped, therefore ECT was restarted
along with olanzapine 10mg a day. Other than these case
reports, there are no clinical trials regarding the use of
ECT in chronic catatonia.
Since there are only a few reports of chronic catatonia
and its treatment, we describe the successful treatment
of a patient with catatonic symptoms of over six months
with ECT.
Case presentation
A 29-year-old South Asian woman was admitted to hos-
pital because of poor food intake. Her condition had
progressively worsened over the past seven months. The
family reported that she was very slow in her move-
ments. She kept food in her mouth without chewing or
swallowing. She also maintained the same posture for
long periods. Her speech had gradually reduced in quan-
tity. In the month prior to admission, she was unable to
carry out activities such as eating, bathing and dressingwithout help. There was no history of fever, loss of con-
sciousness or seizures.
On examination, the patient was mute and staring
vacantly into space. Her movements were very slow. She
maintained uncomfortable postures for long periods,
such as the psychological pillow and holding her arms
over her head in a prayer-like manner. There was auto-
matic obedience and mitgehen. Tone was increased in
all four limbs and waxy flexibility was present. There
was no echolalia, echopraxia, mannerisms or stereotypy.
There were no periods of motor excitement. There were
no focal neurological signs. Her cardiovascular, respira-
tory system and abdominal examination were normal.
On admission, her Bush-Francis Catatonia Rating Scale
score was 24.
A full blood count, liver function, renal function,
fasting blood sugar, erythrocyte sedimentation rate (ESR)
and a computed tomography (CT) scan of the brain
were all normal. Antinuclear antibody tests were nega-
tive. Her short Synacthen test and thyroid function test
(TSH, T3, T4) results were normal.
She first developed psychotic symptoms in 2008.
Treatment was commenced in 2009 but, after four
months, she defaulted on treatment. She became preg-
nant in 2010. Although she had paranoid symptoms
during the antenatal period, she did not seek treatment.
Her symptoms worsened after the delivery of the baby.
Her movements became slow, she was withdrawn and
her self-care was poor. Because of the illness, she was
unable to care for the baby. In June 2011, seven months
after the delivery of her baby, she was admitted to
hospital with catatonic features. She recovered after
administration of four ECTs. She defaulted on treatment
again in November 2011 and became paranoid and with-
drawn. Her level of functioning gradually deteriorated.
By April 2012, she was almost mute and needed help
to carry out activities such as eating and dressing. The
family sought psychiatric treatment and she was treated
with mirtazapine 15mg for three weeks and then
venlafaxine 150mg and lithium carbonate 400mg for
three months. Since there was poor response, treatment
was changed to risperidone. Because her condition
deteriorated further, she was admitted to hospital in
November 2012.
After admission to hospital, the patient was treated
with oral lorazepam 4mg twice a day. There was only
slight improvement in speech and intake of food after
seven days of treatment. ECT was then commenced
using a Thymatron System IV machine (Somatics Inc.,
Lake Bluff, IL, USA). Bilateral ECT was administered
three times a week. Initially, 15% energy was given (76mC)
and this was gradually increased to 200% (1008mC)
because she did not have adequate seizures. After 10
ECTs, significant reduction in catatonic symptoms was
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with others and her self-care improved. Her Bush-Francis
Catatonia Rating Scale score was 12. She received a total
of 17 ECTs. By this time, most of the catatonic symptoms
had disappeared and her Bush-Francis Catatonia Rating
Scale score was 3. Olanzapine was commenced and
gradually increased to 30mg a day. She was discharged
after one month in hospital.
Two weeks after discharge olanzapine was stopped
because she developed galactorrhoea. Aripiprazole was
commenced and the dose was gradually increased to
60mg a day because of the reappearance of slowness,
reduced speech and rigidity. Since the symptoms did not
improve, she was readmitted and a further four ECTs were
given, after which the catatonic symptoms disappeared.
She continues to be well on aripiprazole 60mg a day.
Discussion
This patient, with catatonic symptoms of six months
duration, showed poor response to antidepressants and
antipsychotics. Treatment with lorazepam for seven days
did not result in any significant improvement. She reco-
vered after the administration of 17 ECTs.
Since the DSM −5 does not contain a category of
‘schizophrenia, catatonic type’, the clinical features in this
patient support a diagnosis of ‘catatonia associated with
another mental disorder’ using the specifier as a fifth
digit [13]. Interestingly, since there is no separate cat-
egory for catatonia of prolonged duration, this patient
could also be classified as ‘unspecified catatonia’.
There is a lack of consensus regarding the definition
of chronic catatonia. Most of the evidence about chronic
catatonia is based on case reports. The duration of
symptoms in these case reports vary from one to six
months. Therefore, we suggest that chronic catatonia
should be defined as the presence of catatonia for a
minimum of 30 days.
Some patients with chronic catatonia experience con-
tinuous symptoms while others have recurrent episodes,
especially when treatment is discontinued [6,7]. In our
patient, the symptoms recurred about a month after the
discontinuation of ECT. There is genetic evidence that
MLC1 polymorphisms are specifically associated with
periodic catatonia, a variety of chronic catatonia [14]. In
a patient with recurrent episodes of catatonia lasting two
to three months, a magnetic resonance imaging scan
revealed mega cisterna magna that was mildly and dif-
fusely compressing the left cerebellum and causing pres-
sure scalloping of the internal table of the skull vault in
the left occipital region [15]. These findings suggest that
future studies should explore the concept of recurrent
catatonia.
Although benzodiazepines and ECT are recommended
for the treatment of acute catatonia, treatment optionsfor chronic catatonia have not been discussed exten-
sively. Antipsychotics do not appear to be effective in
terminating chronic catatonic symptoms although they
may be effective in preventing recurrence [6].
Case reports indicate that both bilateral ECT and
ultrabrief pulse ECT are effective in the treatment of
chronic catatonia. ECT is also effective in patients who
do not have an adequate response to lorazepam [11].
Because there are only three case reports of the use of
ECT in chronic catatonia, it is difficult to estimate the
number of treatments needed for clinical response. One
patient with chronic catatonia improved with eight ECTs
while the other required 68 ECTs [11,12]. Our patient
required a total of 21 ECTs. These reports suggest that
some patients with chronic catatonia need a large number
of ECTs for adequate clinical response.
Although the only randomized trial showed that
lorazepam is not effective in the treatment of chronic
catatonia, case reports indicate that, in some patients,
lorazepam is effective. As with ECT, some may need to
be treated for long periods [6-8,10].
Conclusions
Bilateral ECT is effective in the treatment of chronic
catatonia and should be considered as a treatment
option in chronic catatonia. A relapse of symptoms can
occur after the discontinuation of treatment.
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